Addressing strategic challenges for biotech companies
b'In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at DRG Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc gives invaluable insight for bio-pharma companies who are making development and/or commercializing decisions for their clinical programs both for those developing in house and those considering out licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the 'magic triangle' to get an asset to market as fast as possible.
Hosted on Acast. See acast.com/privacy for more information.
'